Feb 17, 2021
Tides Continue to Shift as Novartis' Cosentyx and Eli Lilly's Taltz Experience Early Success in Non-Radiographic Axial Spondyloarthritis
Feb 16, 2021
Spherix Global Insights Releases 2020 Corporate Highlights and Shares Outlook for 2021
Feb 12, 2021
The Impact of COVID-19 on Specialty Physician Practices is Far from Over, Leaving Pharmaceutical Companies to Assess Whether Traditional Promotional Efforts Will Ever Revert to the Pre-COVID Era
Feb 11, 2021
Biogen's Vumerity and Bristol Myers Squibb's Zeposia Show Signs of Early First-Line Success Among Multiple Sclerosis Patients Due to Tolerability and Onboarding Advantages Over Established Agents
Feb 10, 2021
Recent Otezla Growth: A Result of the Amgen Acquisition or Benefiting from the Pandemic?
Jan 29, 2021
Spherix Global Insights Introduces New Service Focusing on Recent Launches in Expanding Immunology, Nephrology, and Neurology Markets
Jan 25, 2021
Unmet Need in Lupus Nephritis Finally Addressed with New FDA Approvals for GlaxoSmithKline's BENLYSTA (belimumab) and Aurinia Pharmaceuticals' LUPKYNIS (voclosporin)
Nov 09, 2020
Increased Biosimilar Prescribing and New Subcutaneous Formulations Are Poised to Impact Biologic Switching in the EU Inflammatory Bowel Disease Market, According to Spherix Global Insights
Oct 29, 2020
Eosinophilic Esophagitis, a Complex, Chronic Autoimmune Condition, Awaits FDA-Approved Therapies, Potentially Including a Biologic Option, According to Spherix Global Insights
Sep 15, 2020
Despite Most Specialty Physician Practices Reopening, Engagement with the Pharmaceutical Industry Continues to be Largely Virtual, Placing Added Pressure on Manufacturers Attempting to Introduce New Therapies
Sep 09, 2020
Recent, Positive Efficacy Data for Janssen's Stelara in Refractory Crohn's Disease Significantly Boost Patient Share for the IL-12/23 Inhibitor, According to Spherix Global Insights
Sep 08, 2020
SGLT2 Inhibitors Could Induce a Seismic Shift in Treatment of Diabetic Kidney Disease in the US, According to Spherix Global Insights
Aug 27, 2020
Spherix Global Insights Releases 2021 Publication Plan and Announces New Service, Launch Dynamix(TM), Fueled by Growing Client Demand
Aug 24, 2020
The US Hyperkalemia Market Remains a Battle Ground Between AstraZeneca's LOKELMA (zirconium sodium cyclosilicate) and Vifor/Relypsa's VELTASSA (patiromer FOS)
Aug 18, 2020
Recent Label Revisions Related to Constipation and Hypertension Generate Minimal Drag on the Decision to Prescribe Amgen/Novartis' Aimovig as a Preventive Treatment for Migraine
Jul 20, 2020
Alternate Mechanism Biologics and Adalimumab Biosimilar Prescribing Increases at the Expense of AbbVie's Humira in the EU5 Inflammatory Bowel Disease Market, Despite the Significant Impact of COVID-19 on Gastroenterology Practitioners
Jul 14, 2020
Treatment of Anemia Among Hematology/Oncology Specialists Spans Diverse Patient Types, Many of Which Have Multiple Contributory Factors
Jul 01, 2020
While Gilead/Galapagos' Filgotinib Will Have to Contend with the Early Success of AbbVie's Rinvoq in the US Rheumatoid Arthritis Market, Eli Lilly's Olumiant is Likely to be the More Formidable Foe in the EU
Jun 30, 2020
Eli Lilly's Reyvow Struggles to Gain Ground in the Acute Segment of the US Migraine Market, Overshadowed by AbbVie's Ubrelvy and Biohaven's Nurtec ODT, According to Spherix Global Insights
Jun 23, 2020
EU5 Rheumatologists Expect the Introduction of Janssen's Tremfya in Psoriatic Arthritis to Blunt Anticipated Growth of Eli Lilly's Taltz, Novartis' Cosentyx, and Pfizer's Xeljanz